secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001104659-24-040008
Event type: regulatory
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharmaceuticals resubmits NDA for etripamil nasal spray to FDA for PSVT
--------------------------------------------------------------------------------

- NDA resubmission for self-administered etripamil nasal spray to treat paroxysmal supraventricular tachycardia (PSVT).
- Resubmission follows FDA Type A meeting after a Refusal to File letter; no new efficacy/safety data requested.
- Package includes restructured AE timing data and reformatted data files to facilitate FDA review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465924040008/0001104659-24-040008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465924040008/tm2410060d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-040008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer